Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.

Tytuł :
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
Autorzy :
Hickson RP; 1 Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, and Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill.
Cole AL; 2 Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill.
Dusetzina SB; 3 Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
Pokaż więcej
Źródło :
Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2019 Jan; Vol. 25 (1), pp. 72-79.
Typ publikacji :
Journal Article
Język :
Imprint Name(s) :
Original Publication: Alexandria, VA : Academy of Managed Care Pharmacy, [2014]-
MeSH Terms :
Drug Labeling*
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Myocardial Infarction/*chemically induced
Pioglitazone/*therapeutic use
Rosiglitazone/*therapeutic use
Adult ; Humans ; Middle Aged ; Pioglitazone/adverse effects ; Retrospective Studies ; Rosiglitazone/adverse effects ; Young Adult
References :
Lancet. 2005 Oct 8;366(9493):1279-89. (PMID: 16214598)
Diabetes Care. 2006 Aug;29(8):1963-72. (PMID: 16873813)
J Am Coll Cardiol. 2007 Apr 24;49(16):1696-704. (PMID: 17448371)
N Engl J Med. 2007 Jun 14;356(24):2457-71. (PMID: 17517853)
N Engl J Med. 2007 Jul 5;357(1):28-38. (PMID: 17551159)
Lancet. 2007 Sep 29;370(9593):1129-36. (PMID: 17905165)
J Card Fail. 2008 Aug;14(6):445-52. (PMID: 18672190)
J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31. (PMID: 18693776)
Diabetes Care. 2009 Jan;32(1):193-203. (PMID: 18945920)
Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1048-52. (PMID: 19655338)
Diabetes Care. 2010 Apr;33(4):823-5. (PMID: 20103549)
Am J Manag Care. 2010 May 01;16(5):e111-6. (PMID: 20455636)
JAMA. 2010 Jul 28;304(4):411-8. (PMID: 20584880)
Arch Intern Med. 2010 Jul 26;170(14):1191-1201. (PMID: 20656674)
N Engl J Med. 2010 Oct 14;363(16):1489-91. (PMID: 20942663)
N Engl J Med. 2010 Nov 25;363(22):2081-4. (PMID: 21083379)
Diabetes Care. 2011 Apr;34(4):916-22. (PMID: 21447663)
Med Care. 2012 Jun;50(6):466-78. (PMID: 22266704)
J Manag Care Pharm. 2012 Nov-Dec;18(9):690-700. (PMID: 23206212)
Am Heart J. 2013 Aug;166(2):240-249.e1. (PMID: 23895806)
N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601)
Diabetes Care. 2015 Jan;38(1):140-9. (PMID: 25538310)
Lancet. 2015 May 23;385(9982):2067-76. (PMID: 25765696)
Res Social Adm Pharm. 2017 Jan - Feb;13(1):193-200. (PMID: 26895807)
Drug Saf. 2016 Aug;39(8):709-14. (PMID: 27000800)
Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):117-118. (PMID: 28067434)
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):857-866. (PMID: 29943442)
Grant Information :
T32 HL007055 United States HL NHLBI NIH HHS; T32 HS000032 United States HS AHRQ HHS
Substance Nomenclature :
0 (Dipeptidyl-Peptidase IV Inhibitors)
05V02F2KDG (Rosiglitazone)
X4OV71U42S (Pioglitazone)
Entry Date(s) :
Date Created: 20181228 Date Completed: 20190405 Latest Revision: 20200225
Update Code :
PubMed Central ID :
Czasopismo naukowe
Background: Medications are increasingly being approved with limited, short-term evidence regarding safety. Regulatory safety concerns may emerge for these drugs but later may be reversed if additional evidence suggests no warning is indicated.
Objective: To describe trends over time in the initiation of rosiglitazone and pioglitazone-both in the thiazolidinedione (TZD) class-and medications from the dipeptidyl peptidase-4 (DPP-4) inhibitor class before and after the FDA removed a black box warning and restricted access program for rosiglitazone regarding an increased risk of myocardial infarction.
Methods: This retrospective study evaluated initiation of TZDs and DPP-4 inhibitors using 2001-2015 administrative claims data from a U.S. commercially insured population. Patients were aged 18-64 years and were new users of either a TZD or DPP-4 inhibitor. Among all patients who were new users of either a TZD or a DPP-4 inhibitor during each quarter-year (Q), the percentage of patients who initiated rosiglitazone, pioglitazone, and DPP-4 inhibitors were calculated.
Results: There were 630,977 patients eligible for the study. During 2007, rosiglitazone initiators decreased from 39.1% to 8.0% in 2007 Q4 when the black box warning was implemented. During 2010, rosiglitazone initiators decreased from 7.6% to 1.0%, as safety evidence accumulated and the restricted access program requirement was announced. Rosiglitazone initiation remained below 1.0%, even after regulatory restrictions were removed in November 2013. Pioglitazone initiation decreased from 46.4% in 2010 Q1 to 14.8% in 2011 Q4 and remained relatively constant between 14.5% and 17.8% after regulatory restrictions for rosiglitazone were removed. After DPP-4 inhibitors first became available in 2006 Q3, initiation of this medication class increased rapidly, stayed relatively constant between 42.8% and 45.5% in 2009, and then quickly rose and remained above 80% from 2012 through 2015.
Conclusions: This case study provides some evidence that adding and later reversing drug safety warnings-particularly those with restricted access requirements-may affect the uptake of the targeted product into the population when multiple clinically relevant treatment alternatives are available (such as type 2 diabetes). Once a treatment falls out of favor, removal of safety warnings and/or restricted access programs may not lead to increased use.
Disclosures: This project was not directly supported by any funding. Hickson was supported by the National Heart, Lung, and Blood Institute through a National Research Service Award (NRSA) training grant (4T32HL007055-41) as a postdoctoral research fellow with the Cardiovascular Disease Epidemiology Program at The University of North Carolina at Chapel Hill (UNC-CH). Cole was supported by a NRSA Predoctoral Traineeship from the Agency for Healthcare Research and Quality sponsored by The Cecil G. Sheps Center for Health Services Research, UNC-CH (grant no. T32-HS000032) and a predoctoral fellowship from the American Foundation for Pharmaceutical Education. Unrelated to this project, Cole was a part-time employee of Truven Health Analytics/IBM Watson Health. Dusetzina has nothing to disclose.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies